How much does ZYKADIA (Ceritinib Capsules) Cost& price without insurance in China?
ZYKADIA® is the commercial brand name of Ceritinib Capsules, a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor developed by Novartis. It exerts anti-tumor activity by selectively inhibiting the kinase activity of ALK, thereby blocking downstream signaling pathways and suppressing the proliferation and survival of ALK-positive tumor cells. It demonstrates activity against many ALK mutations that confer resistance to crizotinib.
Main Indications
Treatment of anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have progressed on or are intolerant to crizotinib.
Common Side Effects
Common adverse reactions: Diarrhea, nausea, vomiting, abdominal pain, fatigue, decreased appetite, weight loss, and visual disorders.
Laboratory abnormalities: Elevated transaminases, increased blood creatinine, hyperglycemia, and decreased white blood cell count.
Severe but manageable risks: Severe gastrointestinal toxicity, hepatotoxicity, interstitial lung disease/pneumonitis, QT interval prolongation, and bradycardia.
Approval Status in China
ZYKADIA® (Ceritinib Capsules, 150mg) was officially approved for marketing in China in May 2018. It is currently a prescription drug included in China’s Category B medical insurance.
Buy ZYKADIA (Ceritinib Capsules) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
